Medtronic's MiniMed 670G - the closest thing yet to an artificial pancreas - has been launched in the US. The so-called 'hybrid closed-loop' system comprises a blood glucose sensor, the MiniMed ...

Classification of Medical Devices and Requirements for Market Approval The various makes and models of pump available use different technological solutions for delivering insulin. To obtain ...

The firm started Dexcom (NASDAQ:DXCM), Insulet (NASDAQ:PODD), and Beta Bionics with Buy ratings, while initiating Tandem Diabetes Care (NASDAQ:TNDM) at Hold. Truist already covers Medtronic’s diabetes ...

Investing.com -- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid ...

By the Journal Star editorial board Jul 6, 2013 Updated Jan 28, 2015 0 ...

Key takeaways: Diabetes technologies have been evolving rapidly in recent years and now serve a wide range of patients. Usage is up for technologies such as automated insulin delivery and ...

Lilly intends to use the real-time CGM tech alongside its pre-filled disposable insulin pens with a software system that can receive data from the pen via an “optional attachment”.

NovoLog (insulin aspart) is a fast-acting insulin used for diabetes treatment. It’s injected 5 to 10 minutes before meals. It may be prescribed with other insulins or oral diabetes drugs.

CHICAGO — For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related events, with consistent findings in further analyses ...

The pancreas plays a role in diabetes because it produces insulin and helps regulate blood sugar levels. We look into the links between diabetes and the pancreas.

In my experience, comments like these always worsen in summer, when either my insulin pump or glucose monitor is more likely to be on show, even though I’ve never actively tried to hide the ...

Dexcom gets $104 target, expected to gain share in non-insulin diabetes segments through 2025. Geopolitical tensions, Fed uncertainty, and fast-moving headlines are driving July volatility.